Carbazole Carboxamide Compounds for Selective Btk Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that effectively inhibit Bruton's tyrosine kinase (Btk) with selectivity over Jak2 tyrosine kinase and improved potency in the whole blood BCR-stimulated CD69 expression assay, while also having desirable stability, bioavailability, and therapeutic index for the treatment of various diseases.
Innovation Solution
Development of carbazole carboxamide compounds that act as potent Btk inhibitors, selective over Jak2 tyrosine kinase, with improved potency in the whole blood BCR-stimulated CD69 expression assay, and possessing desirable stability, bioavailability, and therapeutic index for pharmaceutical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to inhibit Btk with high potency, then therapeutic effectiveness improves, but selectivity over Jak2 kinase may be reduced
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the carbazole core structure. Different R groups (R1-R6) are strategically placed at specific locations to create localized interactions that enhance Btk binding affinity while maintaining selectivity against Jak2 through position-specific steric or electronic effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types (halogens, alkyl groups, aryl groups), substituent positions, and molecular weight within the carbazole scaffold. These parameter modifications allow optimization of the balance between Btk inhibition potency and Jak2 selectivity through structure-activity relationship (SAR) analysis.
2Object-affected harmful factors
If compound structure is optimized for kinase selectivity, then off-target effects are reduced, but pharmacokinetic properties such as bioavailability and stability may be compromised
Solution Approach 1:
The patent applies universality by designing the carbazole carboxamide core structure to simultaneously fulfill multiple functions: (1) providing kinase binding affinity through the carboxamide group, (2) enabling selectivity through the carbazole aromatic system, and (3) ensuring pharmacokinetic stability through appropriate substituent choices that resist metabolic degradation while maintaining oral bioavailability.
Solution Approach 2:
The patent employs composite material principles by combining the carbazole scaffold with carboxamide functional groups and various substituent moieties (R1-R6) to create a composite molecular structure. This composite approach allows integration of multiple properties: the carbazole provides structural rigidity and aromatic stacking, the carboxamide provides hydrogen bonding capability, and the substituents provide selectivity and pharmacokinetic optimization.
3Reliability
If compound potency is increased through structural modifications, then therapeutic index improves, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: the carbazole core (providing structural framework), the carboxamide group (providing kinase binding), and six substitutable positions (R1-R6) that can be independently optimized. This segmentation allows systematic improvement of therapeutic index by modifying individual segments without redesigning the entire molecule, thereby managing complexity.
Data Source
AI summary
Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: R1 is —C(CH3)2OH, —NHC(=0)C(CH3)3, —N(CH3)2, or —CH2Rd; R2 is CI or —CH3; R3 is H, F, or —CH3; Ra is H or —CH3; Rb is H, F, CI, or —OCH3 Rc is H or F; and Rd is —OH, —OCH3, —NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.